摘要:
The present invention relates to stroke-targeting peptides and use thereof. More specifically, the present invention relates to a stroke-targeting peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 4 and use thereof. The peptide of the present invention can be specifically bound to stroke cells in the subject, and thus can be effectively used in diagnostic markers and kits for stroke, and compositions for drug delivery specific to stroke and pharmaceutical compositions and compositions for imaging stroke.
摘要翻译:本发明涉及中风靶向肽及其用途。 更具体地,本发明涉及包含选自SEQ ID NO:1至SEQ ID NO:4的氨基酸序列及其用途的中风靶向肽。 本发明的肽可以特异性地结合到受试者的中风细胞中,因此可以有效地用于中风诊断标记物和试剂盒,以及用于中风特异性药物递送的组合物和用于成像中风的药物组合物和组合物。
摘要:
The present invention relates to stroke-targeting peptides and use thereof. More specifically, the present invention relates to a stroke-targeting peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 4 and use thereof. The peptide of the present invention can be specifically bound to stroke cells in the subject, and thus can be effectively used in diagnostic markers and kits for stroke, and compositions for drug delivery specific to stroke and pharmaceutical compositions and compositions for imaging stroke.
摘要翻译:本发明涉及中风靶向肽及其用途。 更具体地,本发明涉及包含选自SEQ ID NO:1至SEQ ID NO:4的氨基酸序列的中风靶向肽及其用途。 本发明的肽可以特异性地结合到受试者的中风细胞中,因此可以有效地用于中风诊断标记物和试剂盒,以及用于中风特异性药物递送的组合物和用于成像中风的药物组合物和组合物。
摘要:
Provided are a cross-bridged tetraaza macrocyclic compound of a novel structure that can be used, for example, as a contrast agent for diagnostic imaging or a radiopharmaceutical and a method for preparing the same.The disclosed tetraaza macrocyclic compound is able to form a stable metal complex at a lower temperature and allows easy conjugation with a bioactive substance or a chemically active substance, when compared to the existing cross-bridged tetraaza macrocyclic compounds.
摘要:
Provided are a contrast agent for optical imaging, a use thereof and an apparatus using the same.The contrast agent for optical imaging of the present disclosure allows optical imaging without requiring a fluorophore or a luminophore. As a result, the optical images can be acquired without changing the physicochemical properties of a substrate. The contrast agent for optical imaging of the present disclosure may be used as an optical/nuclear bimodal imaging contrast agent for many applications, and allows radiation therapy as well as monitoring of a therapeutic effect thereof through optical imaging at the same time. Further, when a fluorophore is attached thereto, light emission may be enhanced without energy input from outside since light is emitted from the fluorophore, thereby increasing luminescence intensity and improving tissue penetration.
摘要:
Provided are a cross-bridged tetraaza macrocyclic compound of a novel structure that can be used, for example, as a contrast agent for diagnostic imaging or a radiopharmaceutical and a method for preparing the same.The disclosed tetraaza macrocyclic compound is able to form a stable metal complex at a lower temperature and allows easy conjugation with a bioactive substance or a chemically active substance, when compared to the existing cross-bridged tetraaza macrocyclic compounds.